Medisafe Study: Self-Reported Adherence Data Are Consistent with Prescription Refill Claims

March 7th, 2018
Research

Medisafe, the leading medication management platform with over four million registered users, announced today the first wave of results from a novel study, which among other objectives, measures the accuracy of self-reported outcomes (SROs). Medisafe’s study was conducted in partnership with the leading global provider of information, innovative technology solutions and contract research services focused on healthcare data. The initial results shine a positive light on the predictive power of self-reported adherence data.

The study methodology entailed mapping users and their self-reported adherence data to their corresponding prescription claims using a HIPAA-compliant, non-identification process. The results show that the medication possession ratio (MPR) for Medisafe users taking antihypertensives and novel oral anticoagulants (NOACs) is on average 7 to 9% higher than the adherence they report on Medisafe. MPR is a standard metric used by the healthcare industry to track adherence based on prescription claims.

Included in the table below is a summary of key findings for the first two medication categories analyzed:

 

Importantly, the study results are among the first to report the accuracy of patient self-reporting of their medication adherence. A prevailing hypothesis until now has been that self-reporting in healthcare mobile apps is often exaggerated due to alert fatigue or patient “cheating.”

“Historically pharma, payers and the broader care continuum have been skeptical of self-reported data, often dismissing it as biased and inflated. On the contrary, with this study we’ve shown that Medisafe’s self-reported adherence rates are actually lower than industry-standard measures,” says Jon Michaeli, EVP of Strategic Partnerships at Medisafe. “We now have evidence that Medisafe’s adherence data are a trustworthy, insightful complement to traditional data sources. Because we calculate adherence in real-time [at the medication dose level], pharma, payers and other industry stakeholders should no longer be in the dark about medication adherence at critical points in the patient journey, when they have a fleeting opportunity to intervene and correct course.”

In the coming months, Medisafe will continue to release results from the landmark study, including data regarding the platform’s impact on patient adherence to a number of different types of medication.